Lexeo Therapeutics LXEO
NASDAQ LXEO
$3.07 +0.01 (+0.33%)
At close: Nov 11, 2026 · 4:00 PM EST

Lexeo Therapeutics (LXEO) Gains (Losses) on Sale of Assets & Investments (2025 - 2026)

Updated

Lexeo Therapeutics (LXEO) posted Non Operating Investment Income of -$156,000 for Q2 2026, compared with $41,000 a year earlier.

Analysis

Lexeo Therapeutics (LXEO) Gains (Losses) on Sale of Assets & Investments (2025 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Non Operating Investment Income at Lexeo Therapeutics was -$396,000; for FY2025, it was $291,000.

  • In prior years, Lexeo Therapeutics' Non Operating Investment Income was -$103,000 in FY2024.
  • Quarterly Non Operating Investment Income has run from a low of -$330,000 in Q1 2026 to a high of $49,000 in Q1 2025 over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gains on Sales (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Lexeo Therapeutics 240.59 Mn -419.82 Mn - -156,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -156,000.00
Mar 31, 2026 -330,000.00
Dec 31, 2025 99,000.00
Sep 30, 2025 102,000.00
Jun 30, 2025 41,000.00
Mar 31, 2025 49,000.00
API Access

Lexeo Therapeutics Gains (Losses) on Sale of Assets & Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=LXEO&period=max&api_key=YOUR_API_KEY